I'm LongbridgeAI, I can summarize articles.Callan JMB (CJMB) shares surged nearly 50% after hours following a strategic partnership with Alabama State University to build an integrated pharmaceutical manufacturing ecosystem. Under the deal, Callan JMB provides logistics and supply chain support in exchange for 21% of gross revenue, potentially generating $105 million annually. Despite this positive news, the company faces significant challenges, including a Nasdaq notice regarding its sub-$1 stock price compliance deadline.
Callan JMB Inc. (NASDAQ:CJMB) shares are trending on Friday.
Shares of the Texas-based integrative logistics and supply chain management company climbed 49.84% to $1.29 after the bell on Thursday following the announcement that Callan JMB signed a strategic partnership with Alabama State University to build an integrated pharmaceutical manufacturing ecosystem.
Deal Terms Could Bring In $105 Million Annually
Under the partnership, Callan JMB will provide operational support, including logistics, regulatory compliance, warehousing and supply chain management. In return, it will receive 21% of the gross revenue generated from qualifying pharmaceutical manufacturing operations.
Management believes the initiative could ultimately generate annual gross revenues approaching $500 million, representing approximately $105 million in annual revenue for the company.
“This partnership represents far more than a new business opportunity,” said Wayne Williams, Chief Executive Officer of Callan JMB.
Wayne Williams, Chief Executive Officer of Callan JMB, said, “This partnership represents far more than a new business opportunity.”
Nasdaq Notice
According to an early-July Securities and Exchange Commission filing, Callan JMB received a Nasdaq notice on Jun. 29 for falling below the $1 minimum bid price requirement, giving the company until Dec. 28 to regain compliance.
Trading Metrics, Technical Analysis
Callan has a market capitalization of $4.85 million, a 52-week high of $5.88 and a 52-week low of $0.65.
The Relative Strength Index (RSI) of CJMB stands at 57.61.
The stock’s price has fallen by 83.35% over the past 12 months.
Currently, CJMB is trading close to its annual low.
The healthcare company’s sharp stock decline and weak market position suggest that it continues to face significant pressure. These challenges point to increased risk and show that stronger signs of recovery are needed before investor confidence can be restored.
Price Action: CJMB closed the regular session on Thursday at $0.86, up 16.51%, according to Benzinga Pro.
Benzinga’s Edge Stock Rankings indicate CJMB stock has a negative price trend across all time frames.
Disclaimer: This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.
Read Also: Elon Musk Says Engines 'Didn't Start' — SpaceX Stock Trending After Hours As Starship Test Aborts
Photo Courtesy: Gorodenkoff on Shutterstock.com